Physician profile
Robert A Muller
NPI 1053339408
$1,047.84
in general payments reported to CMS, 2019-2025
15 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $343 · 2023: $159 · 2024: $98.96 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $437.09 | 2021-2024 | |
| Abbvie INC. | $258.81 | 2021-2025 | |
| Janssen Biotech, INC. | $49.80 | 2022-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $45.67 | 2024-2025 | Sotyktu |
| Kerecis Limited | $44.75 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Biofrontera INC. | $34.50 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $29.39 | 2022 | |
| Organogenesis INC. | $24.50 | 2025 | Via Matrix |
| Convatec INC. | $20.43 | 2025 | |
| Ucb, INC. | $20.32 | 2025 | Bimzelx |
| Leo Pharma INC. | $18.60 | 2022 | |
| Celgene Corporation | $17.41 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $17.19 | 2025 | Libtayo |
| Incyte Corporation | $15.60 | 2022 | |
| Galderma Laboratories, L.P. | $13.78 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.